Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal

This article was originally published in PharmAsia News

Executive Summary

Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.

You may also be interested in...



Pursuing Productive Pharma Partnerships In Korea

Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.

AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads

Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.

Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results

The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel